期刊论文详细信息
Experimental Hematology & Oncology 卷:11
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Review
Wenbo Wang1  Xiang Yuan2  Xuejiao Yang3  Xiao Wang3  Yueying Wang3 
[1] Department of Oncology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, 200072, Shanghai, China;
[2] Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 610041, Chengdu, China;
[3] Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China;
关键词: T cells;    Natural killer cells;    Chimeric antigen receptor;    Cancer;    Cellular immunotherapy;   
DOI  :  10.1186/s40164-022-00341-7
 received in 2022-08-22, accepted in 2022-09-29,  发布年份 2022
来源: Springer
PDF
【 摘 要 】

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent achievement in the clinical immunotherapy of hematological malignant tumors, leading to a rapid development of cellular immunotherapy in cancer treatment. Scientists are also aware of the prospective advantages of CAR engineering in cellular immunotherapy. Due to various limitations such as the serious side effects of CAR-T therapy, researchers began to investigate other immune cells for CAR modification. Natural killer (NK) cells are critical innate immune cells with the characteristic of non-specifically recognizing target cells and with the potential to become “off-the-shelf” products. In recent years, many preclinical studies on CAR-engineered NK (CAR-NK) cells have shown their remarkable efficacy in cancer therapy and their superiority over autologous CAR-T cells. In this review, we summarize the generation, mechanisms of anti-tumor activity and unique advantages of CAR-NK cells, and then analyze some challenges and recent clinical trials about CAR-NK cells therapy. We believe that CAR-NK therapy is a promising prospect for cancer immunotherapy in the future.

【 授权许可】

CC BY   
© The Author(s) 2022

【 预 览 】
附件列表
Files Size Format View
RO202304220685002ZK.pdf 1930KB PDF download
13046_2023_2672_Article_IEq1.gif 1KB Image download
Fig. 21 48KB Image download
【 图 表 】

Fig. 21

13046_2023_2672_Article_IEq1.gif

【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  • [28]
  • [29]
  • [30]
  • [31]
  • [32]
  • [33]
  • [34]
  • [35]
  • [36]
  • [37]
  • [38]
  • [39]
  • [40]
  • [41]
  • [42]
  • [43]
  • [44]
  • [45]
  • [46]
  • [47]
  • [48]
  • [49]
  • [50]
  • [51]
  • [52]
  • [53]
  • [54]
  • [55]
  • [56]
  • [57]
  • [58]
  • [59]
  • [60]
  • [61]
  • [62]
  • [63]
  • [64]
  • [65]
  • [66]
  • [67]
  • [68]
  • [69]
  • [70]
  • [71]
  • [72]
  • [73]
  • [74]
  • [75]
  • [76]
  • [77]
  • [78]
  • [79]
  • [80]
  • [81]
  • [82]
  • [83]
  • [84]
  • [85]
  • [86]
  • [87]
  • [88]
  • [89]
  • [90]
  • [91]
  • [92]
  • [93]
  • [94]
  • [95]
  • [96]
  • [97]
  • [98]
  • [99]
  • [100]
  • [101]
  • [102]
  • [103]
  • [104]
  • [105]
  • [106]
  • [107]
  • [108]
  • [109]
  • [110]
  • [111]
  • [112]
  • [113]
  • [114]
  • [115]
  • [116]
  • [117]
  • [118]
  • [119]
  • [120]
  • [121]
  • [122]
  • [123]
  • [124]
  • [125]
  • [126]
  • [127]
  • [128]
  • [129]
  • [130]
  • [131]
  • [132]
  • [133]
  • [134]
  • [135]
  • [136]
  • [137]
  • [138]
  • [139]
  • [140]
  • [141]
  • [142]
  • [143]
  • [144]
  • [145]
  • [146]
  • [147]
  • [148]
  • [149]
  • [150]
  • [151]
  • [152]
  • [153]
  • [154]
  • [155]
  • [156]
  • [157]
  • [158]
  • [159]
  • [160]
  • [161]
  • [162]
  • [163]
  • [164]
  • [165]
  • [166]
  • [167]
  • [168]
  • [169]
  • [170]
  • [171]
  • [172]
  • [173]
  • [174]
  • [175]
  • [176]
  • [177]
  • [178]
  • [179]
  • [180]
  • [181]
  • [182]
  • [183]
  • [184]
  • [185]
  • [186]
  • [187]
  • [188]
  • [189]
  • [190]
  • [191]
  • [192]
  • [193]
  • [194]
  • [195]
  • [196]
  • [197]
  • [198]
  • [199]
  • [200]
  • [201]
  • [202]
  • [203]
  • [204]
  • [205]
  • [206]
  • [207]
  • [208]
  • [209]
  • [210]
  • [211]
  • [212]
  • [213]
  • [214]
  • [215]
  • [216]
  文献评价指标  
  下载次数:1次 浏览次数:0次